위부전 마비 치료제 시장 규모는 향후 수년간 강력한 성장세를 보이며 2029년까지 연평균 5.9%의 연평균 복합 성장률(CAGR)로 72억 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 당뇨병 유병률 증가, 고령화, 인지율 및 진단율 증가, 의료비 지출 증가, 정부 및 민간 자금 투입 등에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 소화기병학의 발전, 진단 기술 향상, 기술 혁신, 연구 자금, 공동 연구 노력 등이 있습니다.
당뇨병 유병률 증가가 위부전 마비 치료제 시장 확대를 견인할 것으로 예상됩니다. 당뇨병은 인슐린 분비 부족 또는 인슐린을 효과적으로 사용할 수 없는 체질로 인한 혈당 상승을 특징으로 하는 만성질환입니다. 당뇨병 환자 증가는 좌식 생활습관, 식습관 장애, 유전적 소인, 도시화, 고령화, 의료 서비스 접근성 제한, 전 세계 비만율 증가 등의 요인에 기인합니다. 위마비 치료제는 메스꺼움, 구토, 위 배출 지연 등의 증상을 완화하기 위해 당뇨병 환자에게 처방되는 것이 일반적입니다. 이 약들은 위 운동을 개선하고 당뇨병과 관련된 위마비 환자의 삶의 질을 향상시키는 것을 목표로 합니다. 예를 들어 2024년 3월 영국 정부 부서인 Office for Health Improvement &Disparities에 따르면 2022년 3월과 2023년 3월 사이에 권장되는 8가지 치료 과정을 모두 받는 1형 당뇨병 환자의 비율이 22% 증가했다고 합니다. 증가했으며, 2형 당뇨병 환자의 비율은 21% 증가했습니다. 또한 HbA1c 목표치를 달성한 사람의 비율은 37.9%로 상승하여 전국 당뇨병 감사(NDA)가 보고한 사상 최고치를 기록했습니다. 따라서 당뇨병 유병률 증가는 위부전 마비 치료제 시장의 성장에 기여하고 있습니다.
위마비 치료제 분야의 주요 기업은 시장 경쟁력을 강화하기 위해 Gimoti(메토클로프라미드) 비강 분무제와 같은 혁신적인 의약품을 도입하는 데 주력하고 있습니다. 소화관 운동을 강화하여 위장의 공극화를 촉진합니다. 소화관을 거치지 않고 코 점막을 통해 직접 혈류로 흡수됩니다. 예를 들어 2022년 4월 미국 제약회사 Evoke Pharma Inc.는 미국 식품의약국(FDA)이 GIMOTI(메토클로프라미드) 비강 분무제에 대한 신약 독점권을 부여했다고 밝혔습니다. 이 독점권은 해치-왁스만법(Hatch-Waxman Act)에 따라 최초 승인일로부터 3년간 Evoke사에 독점 판매권을 부여하는 것으로, 제네릭 의약품과의 경쟁으로부터 이 제품을 보호합니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 위마비 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 위마비 치료제 시장 : 성장률 분석
- 세계의 위마비 치료제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 위마비 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 위마비 치료제 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 위마비 치료제 시장 : 약제 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 일반의약품(OTC)
- 처방약
- 세계의 위마비 치료제 시장 : 질환 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 당뇨병성 위마비
- 수술후 위마비
- 특발성 위마비
- 기타 질병의 유형
- 세계의 위마비 치료제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 주사제
- 기타 투여 경로
- 세계의 위마비 치료제 시장 약제 클래스별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 소화관 운동 촉진제
- 항구토제
- 프로톤 펌프 저해제
- 기타 약물 클래스
- 세계의 위마비 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 약국
- 클리닉
- E-Commerce
- 세계의 위마비 치료제 시장 일반의약품(OTC)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 제산제
- 구토 방지약
- 항구토제
- 소화 효소 보충제
- 세계의 위마비 치료제 시장 처방약의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 소화관 운동 촉진제
- 항구토제
- 항생제
- 항우울제
제7장 지역별·국가별 분석
- 세계의 위마비 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 위마비 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 위마비 치료제 시장 : 경쟁 구도
- 위마비 치료제 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- Sanofi SA. Overview, Products and Services, Strategy and Financial Analysis
- AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- Abbott Laboratories
- GSK plc
- Takeda Pharmaceutical Inc.
- Teva Pharmaceutical Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Bausch Health Companies Inc.
- Eisai Co. Ltd.
- Evoke Pharma Inc.
- Cadila Pharmaceuticals
- Cipla Ltd.
- Neurogastrx Inc.
- Ipca Laboratories Ltd.
- ANI Pharmaceuticals Inc.
- Salix Pharmaceuticals Inc.
- Vanda Pharmaceuticals Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 위마비 치료제 시장 2029 : 새로운 기회를 제공하는 국가
- 위마비 치료제 시장 2029 : 새로운 기회를 제공하는 부문
- 위마비 치료제 시장 2029 : 성장 전략
제36장 부록
KSA
Gastroparesis drugs are medications utilized to handle and address gastroparesis, a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting, and abdominal discomfort. Typically, these medications consist of prokinetics to enhance stomach motility, antiemetics to regulate nausea and vomiting, and drugs to alleviate pain and other associated symptoms.
The primary categories of gastroparesis drugs consist of over-the-counter (OTC) medications and prescription drugs. Over-the-counter (OTC) drugs are those available for purchase without a prescription from a healthcare provider. These medications are utilized for treating various forms of gastroparesis, including diabetic gastroparesis, post-surgical gastroparesis, idiopathic gastroparesis, among others, and are administered through various routes such as oral ingestion, injection, and others. They encompass various types of drugs such as prokinetic agents, antiemetics, proton pump inhibitors, among others, which are distributed through hospitals, pharmacies, clinics, and online platforms.
The gastroparesis drugs market research report is one of a series of new reports from The Business Research Company that provides gastroparesis drugs market statistics, including gastroparesis drugs industry global market size, regional shares, competitors with a gastroparesis drugs market share, detailed gastroparesis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis drugs industry. This gastroparesis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.39 billion in 2024 to $5.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to side effects of existing treatments, gastrointestinal motility research, clinical need, patient advocacy, and regulatory support.
The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $7.2 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes, the aging population, rising awareness and diagnosis rates, increase in healthcare expenditure, and government and private funding. Major trends in the forecast period include advancements in gastroenterology, improved diagnostic techniques, technological innovations, research funding, and collaborative research efforts.
The growing prevalence of diabetes is expected to drive the expansion of the gastroparesis drugs market. Diabetes is a chronic condition characterized by elevated blood sugar levels due to insufficient insulin production or the body's inability to effectively use insulin. The rise in diabetes cases is attributed to factors such as sedentary lifestyles, poor dietary habits, genetic predisposition, urbanization, aging populations, limited healthcare access, and increasing obesity rates globally. Gastroparesis drugs are commonly prescribed to diabetic patients to alleviate symptoms such as nausea, vomiting, and delayed gastric emptying-gastrointestinal issues that are frequent complications of diabetes. These medications aim to improve gastric motility and enhance the quality of life for those with diabetes-related gastroparesis. For example, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, the increase was 21%. Additionally, the percentage of individuals achieving target HbA1c levels rose to 37.9%, the highest ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is contributing to the growth of the gastroparesis drugs market.
Major players in the gastroparesis drugs sector are directing their efforts towards introducing innovative medications, such as the Gimoti (metoclopramide) nasal spray, to enhance their market competitiveness. Gimoti (metoclopramide) nasal spray is a pharmaceutical designed to alleviate symptoms of gastroparesis in adults, fostering stomach emptying by bolstering gastrointestinal motility. By circumventing the gastrointestinal tract, it is absorbed directly into the bloodstream via the nasal mucosa. For example, in April 2022, Evoke Pharma Inc., a pharmaceutical company based in the United States, disclosed that the U.S. Food and Drug Administration (FDA) had granted GIMOTI (metoclopramide) nasal spray new drug product exclusivity. This exclusivity affords Evoke exclusive marketing privileges for three years following the initial approval date, as per the Hatch-Waxman Act, shielding the product from generic competition.
In June 2022, Eagle Pharmaceuticals Inc., a pharmaceutical firm headquartered in the United States, completed the acquisition of Acacia Pharma Group plc for $102 million (€94.7 million). Through this acquisition, Eagle Pharmaceuticals intends to broaden its range of offerings by integrating Acacia's FDA-approved hospital products, BARHEMSYS and BYFAVO, which cater to unmet clinical demands in acute care environments. Acacia Pharma Group plc, based in the United Kingdom, specializes in providing antiemetic medications utilized in gastroparesis treatment.
Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc, Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.
North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gastroparesis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The gastroparesis drugs market consists of sales of ondansetron, metoclopramide, amitriptyline, and erythromycin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gastroparesis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gastroparesis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gastroparesis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroparesis drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Type: Over-the-counter (OTC) Drugs; Prescription Drugs
- 2) By Drug Class: Prokinetic Agents; Antiemetic Drugs; Proton Pump Inhibitors; Other Drug Classes
- 3) By Disease Type: Diabetic Gastroparesis; Post-Surgical Gastroparesis; Idiopathic Gastroparesis; Other Disease Types
- 4) By Route Of Administration: Oral; Injectables; Other Routes Of Administration
- 5) By Distribution Channel: Hospitals; Pharmacies; Clinics; E-commerce
- Subsegments:
- 1) Over-the-counter (OTC) Drugs: Antacids; Anti-Nausea Medications; Antiemetics; Digestive Enzyme Supplements
- 2) Prescription Drugs: Prokinetic Agents; Antiemetic Drugs; Antibiotics; Antidepressants
- Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi SA.; AstraZeneca plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gastroparesis Drugs Market Characteristics
3. Gastroparesis Drugs Market Trends And Strategies
4. Gastroparesis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Gastroparesis Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Gastroparesis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Gastroparesis Drugs Market Growth Rate Analysis
- 5.4. Global Gastroparesis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Gastroparesis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Gastroparesis Drugs Total Addressable Market (TAM)
6. Gastroparesis Drugs Market Segmentation
- 6.1. Global Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Over-The-Counter (OTC) Drugs
- Prescription Drugs
- 6.2. Global Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Diabetic Gastroparesis
- Post-Surgical Gastroparesis
- Idiopathic Gastroparesis
- Other Disease Types
- 6.3. Global Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectables
- Other Routes Of Administration
- 6.4. Global Gastroparesis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Prokinetic Agents
- Antiemetic Drugs
- Proton Pump Inhibitors
- Other Drug Classes
- 6.5. Global Gastroparesis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Pharmacies
- Clinics
- E-commerce
- 6.6. Global Gastroparesis Drugs Market, Sub-Segmentation Of Over-the-counter (OTC) Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antacids
- Anti-Nausea Medications
- Antiemetics
- Digestive Enzyme Supplements
- 6.7. Global Gastroparesis Drugs Market, Sub-Segmentation Of Prescription Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Prokinetic Agents
- Antiemetic Drugs
- Antibiotics
- Antidepressants
7. Gastroparesis Drugs Market Regional And Country Analysis
- 7.1. Global Gastroparesis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Gastroparesis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gastroparesis Drugs Market
- 8.1. Asia-Pacific Gastroparesis Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gastroparesis Drugs Market
- 9.1. China Gastroparesis Drugs Market Overview
- 9.2. China Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gastroparesis Drugs Market
- 10.1. India Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gastroparesis Drugs Market
- 11.1. Japan Gastroparesis Drugs Market Overview
- 11.2. Japan Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gastroparesis Drugs Market
- 12.1. Australia Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gastroparesis Drugs Market
- 13.1. Indonesia Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gastroparesis Drugs Market
- 14.1. South Korea Gastroparesis Drugs Market Overview
- 14.2. South Korea Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gastroparesis Drugs Market
- 15.1. Western Europe Gastroparesis Drugs Market Overview
- 15.2. Western Europe Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gastroparesis Drugs Market
- 16.1. UK Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gastroparesis Drugs Market
- 17.1. Germany Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gastroparesis Drugs Market
- 18.1. France Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gastroparesis Drugs Market
- 19.1. Italy Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gastroparesis Drugs Market
- 20.1. Spain Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gastroparesis Drugs Market
- 21.1. Eastern Europe Gastroparesis Drugs Market Overview
- 21.2. Eastern Europe Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gastroparesis Drugs Market
- 22.1. Russia Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gastroparesis Drugs Market
- 23.1. North America Gastroparesis Drugs Market Overview
- 23.2. North America Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gastroparesis Drugs Market
- 24.1. USA Gastroparesis Drugs Market Overview
- 24.2. USA Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gastroparesis Drugs Market
- 25.1. Canada Gastroparesis Drugs Market Overview
- 25.2. Canada Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gastroparesis Drugs Market
- 26.1. South America Gastroparesis Drugs Market Overview
- 26.2. South America Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gastroparesis Drugs Market
- 27.1. Brazil Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gastroparesis Drugs Market
- 28.1. Middle East Gastroparesis Drugs Market Overview
- 28.2. Middle East Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gastroparesis Drugs Market
- 29.1. Africa Gastroparesis Drugs Market Overview
- 29.2. Africa Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gastroparesis Drugs Market Competitive Landscape And Company Profiles
- 30.1. Gastroparesis Drugs Market Competitive Landscape
- 30.2. Gastroparesis Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi SA. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
31. Gastroparesis Drugs Market Other Major And Innovative Companies
- 31.1. Abbott Laboratories
- 31.2. GSK plc
- 31.3. Takeda Pharmaceutical Inc.
- 31.4. Teva Pharmaceutical Inc.
- 31.5. Otsuka Pharmaceutical Co. Ltd.
- 31.6. Bausch Health Companies Inc.
- 31.7. Eisai Co. Ltd.
- 31.8. Evoke Pharma Inc.
- 31.9. Cadila Pharmaceuticals
- 31.10. Cipla Ltd.
- 31.11. Neurogastrx Inc.
- 31.12. Ipca Laboratories Ltd.
- 31.13. ANI Pharmaceuticals Inc.
- 31.14. Salix Pharmaceuticals Inc.
- 31.15. Vanda Pharmaceuticals Inc.
32. Global Gastroparesis Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gastroparesis Drugs Market
34. Recent Developments In The Gastroparesis Drugs Market
35. Gastroparesis Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Gastroparesis Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Gastroparesis Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Gastroparesis Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
